Cargando…
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent prese...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447603/ https://www.ncbi.nlm.nih.gov/pubmed/32606456 http://dx.doi.org/10.1038/s41575-020-0310-z |
_version_ | 1783574335068307456 |
---|---|
author | Banales, Jesus M. Marin, Jose J. G. Lamarca, Angela Rodrigues, Pedro M. Khan, Shahid A. Roberts, Lewis R. Cardinale, Vincenzo Carpino, Guido Andersen, Jesper B. Braconi, Chiara Calvisi, Diego F. Perugorria, Maria J. Fabris, Luca Boulter, Luke Macias, Rocio I. R. Gaudio, Eugenio Alvaro, Domenico Gradilone, Sergio A. Strazzabosco, Mario Marzioni, Marco Coulouarn, Cédric Fouassier, Laura Raggi, Chiara Invernizzi, Pietro Mertens, Joachim C. Moncsek, Anja Rizvi, Sumera Heimbach, Julie Koerkamp, Bas Groot Bruix, Jordi Forner, Alejandro Bridgewater, John Valle, Juan W. Gores, Gregory J. |
author_facet | Banales, Jesus M. Marin, Jose J. G. Lamarca, Angela Rodrigues, Pedro M. Khan, Shahid A. Roberts, Lewis R. Cardinale, Vincenzo Carpino, Guido Andersen, Jesper B. Braconi, Chiara Calvisi, Diego F. Perugorria, Maria J. Fabris, Luca Boulter, Luke Macias, Rocio I. R. Gaudio, Eugenio Alvaro, Domenico Gradilone, Sergio A. Strazzabosco, Mario Marzioni, Marco Coulouarn, Cédric Fouassier, Laura Raggi, Chiara Invernizzi, Pietro Mertens, Joachim C. Moncsek, Anja Rizvi, Sumera Heimbach, Julie Koerkamp, Bas Groot Bruix, Jordi Forner, Alejandro Bridgewater, John Valle, Juan W. Gores, Gregory J. |
author_sort | Banales, Jesus M. |
collection | PubMed |
description | Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted. |
format | Online Article Text |
id | pubmed-7447603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-74476032020-09-02 Cholangiocarcinoma 2020: the next horizon in mechanisms and management Banales, Jesus M. Marin, Jose J. G. Lamarca, Angela Rodrigues, Pedro M. Khan, Shahid A. Roberts, Lewis R. Cardinale, Vincenzo Carpino, Guido Andersen, Jesper B. Braconi, Chiara Calvisi, Diego F. Perugorria, Maria J. Fabris, Luca Boulter, Luke Macias, Rocio I. R. Gaudio, Eugenio Alvaro, Domenico Gradilone, Sergio A. Strazzabosco, Mario Marzioni, Marco Coulouarn, Cédric Fouassier, Laura Raggi, Chiara Invernizzi, Pietro Mertens, Joachim C. Moncsek, Anja Rizvi, Sumera Heimbach, Julie Koerkamp, Bas Groot Bruix, Jordi Forner, Alejandro Bridgewater, John Valle, Juan W. Gores, Gregory J. Nat Rev Gastroenterol Hepatol Consensus Statement Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted. Nature Publishing Group UK 2020-06-30 2020 /pmc/articles/PMC7447603/ /pubmed/32606456 http://dx.doi.org/10.1038/s41575-020-0310-z Text en © The author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Consensus Statement Banales, Jesus M. Marin, Jose J. G. Lamarca, Angela Rodrigues, Pedro M. Khan, Shahid A. Roberts, Lewis R. Cardinale, Vincenzo Carpino, Guido Andersen, Jesper B. Braconi, Chiara Calvisi, Diego F. Perugorria, Maria J. Fabris, Luca Boulter, Luke Macias, Rocio I. R. Gaudio, Eugenio Alvaro, Domenico Gradilone, Sergio A. Strazzabosco, Mario Marzioni, Marco Coulouarn, Cédric Fouassier, Laura Raggi, Chiara Invernizzi, Pietro Mertens, Joachim C. Moncsek, Anja Rizvi, Sumera Heimbach, Julie Koerkamp, Bas Groot Bruix, Jordi Forner, Alejandro Bridgewater, John Valle, Juan W. Gores, Gregory J. Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
title | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
title_full | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
title_fullStr | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
title_full_unstemmed | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
title_short | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
title_sort | cholangiocarcinoma 2020: the next horizon in mechanisms and management |
topic | Consensus Statement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447603/ https://www.ncbi.nlm.nih.gov/pubmed/32606456 http://dx.doi.org/10.1038/s41575-020-0310-z |
work_keys_str_mv | AT banalesjesusm cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT marinjosejg cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT lamarcaangela cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT rodriguespedrom cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT khanshahida cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT robertslewisr cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT cardinalevincenzo cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT carpinoguido cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT andersenjesperb cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT braconichiara cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT calvisidiegof cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT perugorriamariaj cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT fabrisluca cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT boulterluke cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT maciasrocioir cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT gaudioeugenio cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT alvarodomenico cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT gradilonesergioa cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT strazzaboscomario cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT marzionimarco cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT coulouarncedric cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT fouassierlaura cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT raggichiara cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT invernizzipietro cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT mertensjoachimc cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT moncsekanja cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT rizvisumera cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT heimbachjulie cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT koerkampbasgroot cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT bruixjordi cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT forneralejandro cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT bridgewaterjohn cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT vallejuanw cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement AT goresgregoryj cholangiocarcinoma2020thenexthorizoninmechanismsandmanagement |